FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses) 1. Name and Address of Reporting Person* Crescenzo Andrew R.				2. Issuer Name and Ticker or Trading Symbol ENZO BIOCHEM INC [ENZ]							mbol		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last) (First) (Middle) C/O ENZO BIOCHEM, INC, 527 MADISON AVENUE				3. Date of Earliest Transaction (Month/Day/Year) 12/07/2007							/Year)	X Officer (give title below) Other (specify below) Senior Vice President, Finance					
(Street) NEW YORK, NY 10003				4. If Amendment, Date Original Filed(Month/Day/Year)							/Day/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person					
(City) (State) (Zip)				Table I - Non-Derivative Securities Acqu							Securities	ired, Disposed of, or Beneficially Owned					
(Instr. 3) Da		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)		(Instr. 8)		((A) or Disposed of (Instr. 3, 4 and 5)		of (D)	(D) Beneficially Own Reported Transac (Instr. 3 and 4)		ollowing	\ /	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Restricted	d Stock (1)		12/07/2007					A	-	5,000	` ´	(1)	2,000 (2)		D	
			Table II - I					quire	the for d, Disp	m dis	plays a d	curre eficial	ntly valid		spond unle trol numbe		
Security	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/\footnote{\text{Month/Day/\footnote{\text{V}}}}	Transaction 3A. Deemed Execution Date (onth/Day/Year) any		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Owners Form of Derivati Security Direct (I or Indire	Beneficia Ownershi (Instr. 4)	
				С	ode	V	(A)	(D)	Date Exercis		Expiration Date	Title	Amount or Number of Shares				
Repor	ting O	wners															

P (1 0 N /	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer				
Crescenzo Andrew R. C/O ENZO BIOCHEM, INC 527 MADISON AVENUE NEW YORK, NY 10003			Senior Vice President, Finance				

Signatures

/s/ Andrew Crescenzo	12/11/2007
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) On December 7, 2007, the Reporting Person was granted 6,000 shares of Restricted Stock as compensation for service as an officer of the Issuer.
- (2) This number does not include 10,000 shares of Restricted Stock that are not exercisable within 60 days from the date hereof.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.